Braeburn
Develops long-acting implantable and injectable therapies for opioid addiction and chronic pain.
About
Braeburn Pharmaceuticals is focused on developing long-acting implantable and injectable therapies for opioid addiction and chronic pain. Their lead product, Probufine (buprenorphine implant), is FDA-approved for opioid dependence, and another product, CAM2038, is in the NDA refilling process for opioid dependence and in Phase 3 for pain management. The company aims to transform the management of opioid use disorder by eliminating stigma and improving access to treatment. Teams look it up for Biotech, HealthTech, Drug Discovery.
Frequently asked
What does Braeburn do?
Braeburn is a Biotech company that offers Software | hardware | services | marketplace | platform. Teams look it up for HealthTech, Drug Discovery, Biotechnology. It is based in Plymouth Meeting, PA, United States and was founded in 2012. Public records show about 276 people and $133M raised. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has Braeburn raised?
Braeburn has raised a total of $133M in funding. The most recent round on record is Conventional Debt.
Where is Braeburn headquartered?
Braeburn is headquartered in Plymouth Meeting, PA, United States.
When was Braeburn founded?
Braeburn was founded in 2012.
What industry does Braeburn operate in?
Braeburn operates in Biotech, HealthTech, Drug Discovery, Biotechnology, Life Sciences.
How many employees does Braeburn have?
Braeburn has approximately 276 people on record.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.